Clarivate PLC $CLVT Shares Bought by Invenomic Capital Management LP

Invenomic Capital Management LP boosted its holdings in shares of Clarivate PLC (NYSE:CLVT) by 3.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 9,029,414 shares of the company’s stock after purchasing an additional 326,369 shares during the period. Clarivate comprises approximately 1.4% of Invenomic Capital Management LP’s investment portfolio, making the stock its 18th biggest holding. Invenomic Capital Management LP owned approximately 1.37% of Clarivate worth $30,158,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in CLVT. Royal Bank of Canada lifted its position in Clarivate by 96.2% during the first quarter. Royal Bank of Canada now owns 63,630 shares of the company’s stock valued at $250,000 after purchasing an additional 31,197 shares during the period. AQR Capital Management LLC lifted its position in Clarivate by 37.0% during the first quarter. AQR Capital Management LLC now owns 451,872 shares of the company’s stock valued at $1,749,000 after purchasing an additional 122,099 shares during the period. Millennium Management LLC lifted its position in Clarivate by 1,420.4% during the first quarter. Millennium Management LLC now owns 1,188,978 shares of the company’s stock valued at $4,673,000 after purchasing an additional 1,110,774 shares during the period. Goldman Sachs Group Inc. lifted its position in Clarivate by 15.5% during the first quarter. Goldman Sachs Group Inc. now owns 616,250 shares of the company’s stock valued at $2,422,000 after purchasing an additional 82,768 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Clarivate by 13.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,243,683 shares of the company’s stock valued at $4,888,000 after purchasing an additional 144,462 shares during the period. 85.72% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on CLVT. Wall Street Zen upgraded shares of Clarivate from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Royal Bank Of Canada decreased their target price on shares of Clarivate from $5.00 to $3.00 and set a “sector perform” rating for the company in a research report on Wednesday, February 25th. Barclays decreased their target price on shares of Clarivate from $4.00 to $2.40 and set an “underweight” rating for the company in a research report on Wednesday, February 25th. Citigroup decreased their price objective on shares of Clarivate from $4.25 to $2.80 and set a “neutral” rating for the company in a research report on Wednesday, March 4th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Clarivate in a research report on Friday, March 27th. Five analysts have rated the stock with a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, Clarivate currently has a consensus rating of “Reduce” and an average target price of $3.22.

Clarivate Stock Down 3.1%

CLVT stock opened at $2.07 on Thursday. The stock has a market capitalization of $1.32 billion, a P/E ratio of -9.83 and a beta of 1.36. The firm has a 50-day simple moving average of $2.49 and a 200-day simple moving average of $2.70. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 0.89. Clarivate PLC has a 52 week low of $1.66 and a 52 week high of $4.77.

Clarivate (NYSE:CLVT) last released its earnings results on Wednesday, April 29th. The company reported $0.18 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.04. The business had revenue of $585.50 million during the quarter, compared to analysts’ expectations of $569.50 million. Clarivate had a negative net margin of 5.61% and a positive return on equity of 8.82%. The company’s quarterly revenue was down 1.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.14 earnings per share. Clarivate has set its FY 2026 guidance at 0.700-0.800 EPS. Equities analysts forecast that Clarivate PLC will post 0.65 earnings per share for the current fiscal year.

Clarivate Profile

Clarivate plc is a global information and analytics company that provides insights and workflow solutions to accelerate the pace of innovation. The company delivers proprietary data, analytics, and expertise to support research and development in the life sciences, intellectual property management, academic institutions, government agencies, and corporations. Its core offerings include citation and patent databases, drug pipeline analytics, trademark research tools, regulatory compliance solutions, and market intelligence platforms.

Originally part of Thomson Reuters’ Intellectual Property & Science division, Clarivate was established as an independent entity in 2016 following a spin-off transaction.